AIDS

Edited by: Steve Bunk and Eugene Russo S.M. Hammer, D.A. Katzenstein, M.D. Hughes, H. Gundacker, R.T. Schooley, R.H. Haubrich, W.K. Henry, M.M. Lederman, J.P. Phair, M. Niu, M.S. Hirsch, T.C. Merigan, "A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter," The New England Journal of Medicine, 335:1081-90, 1996. (Cited in more than 200 papers since publication) Comments by David A. Katzenstein, associa

The Scientist Staff
Feb 14, 1999

Edited by: Steve Bunk and Eugene Russo
S.M. Hammer, D.A. Katzenstein, M.D. Hughes, H. Gundacker, R.T. Schooley, R.H. Haubrich, W.K. Henry, M.M. Lederman, J.P. Phair, M. Niu, M.S. Hirsch, T.C. Merigan, "A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter," The New England Journal of Medicine, 335:1081-90, 1996. (Cited in more than 200 papers since publication)

Comments by David A. Katzenstein, associate professor of medicine at Stanford University

HIV and AIDS clinical drug trials have progressed at a furious pace in the last few years. In the late 1980s and early 1990s, doctors used nucleoside analogs, mostly zidovudine (AZT), to treat patients with AIDS, but they rarely employed the drugs for persons infected with HIV who had yet to acquire AIDS symptoms. A 1989 study by Paul Volberding of the University of California, San...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?